All In Biotech

Drug Trial Radar · NCT05383196

Onvansertib + Paclitaxel In TNBC

A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breast Cancer Patients

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 30, 2022

Primary completion

Dec 15, 2026

Study completion Feb 15, 2029

Sponsor

Lead sponsor
Antonio Giordano, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cardiff Oncology
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: * Onvansertib * Paclitaxel

Conditions

  • Breast Cancer
  • Invasive Breast Cancer
  • Unresectable Breast Carcinoma
  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Inflammatory Breast Cancer
  • Triple Negative Breast Cancer (TNBC)
  • Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Negative Breast Carcinoma

Interventions

  • OnvansertibDrug

    oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.

  • PaclitaxelDrug

    once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting Toxicity (DLT)-Phase IbTime frame: during the first cycle of therapy (28 days).
  2. Incidence of Grade 3 or Higher Treatment-Related Toxicity- Phase IbTime frame: during the first cycle of therapy (28 days).
  3. Overall Response Rate (ORR) Phase IITime frame: Every 8 weeks until disease progression, in average 24 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconness Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.